Business Context and Reporting Period
This Form 8-K was filed by Lantheus Holdings, Inc. on December 2, 2022, reporting a material definitive agreement entered into on that date. The filing details the refinancing of the company's existing credit facilities by its wholly-owned subsidiary, Lantheus Medical Imaging, Inc. (LMI), and announces a proposed offering of convertible senior notes.
Key Financial Metrics and Capital Structure
- Refinancing Transaction: LMI replaced an existing $400.0 million facility ($200.0 million term loan and $200.0 million revolving credit) with a new facility structure.
- New Revolving Facility: A $350.0 million five-year revolving credit facility, including a $20.0 million sub-facility for letters of credit and a $10.0 million sub-facility for swingline loans.
- Delayed Draw Term Loan: A new $100.0 million delayed draw term loan facility, intended to be drawn only if the proposed notes offering is not consummated.
- Repayment of Old Debt: Approximately $167.6 million of cash on hand was used to repay the outstanding principal of the old facility in full, along with related interest and fees.
- Proposed Offering: The company proposes to offer $500.0 million in aggregate principal amount of convertible senior notes due 2027, with an option for an additional $75.0 million.
- Stock Repurchase Authorization: The board authorized the repurchase of up to $150.0 million of common stock, with up to $75.0 million expected to be funded from the notes offering proceeds.
Material Changes Versus Prior Period
- Debt Capacity Increase: The total committed credit facility increased from $400.0 million under the old agreement to $450.0 million under the new agreement ($350.0 million revolving + $100.0 million delayed draw term).
- Term Extension: The new revolving facility extends the maturity date to December 2, 2027, compared to the old term loan which was scheduled to mature on June 27, 2024.
- Interest Rate Structure: The new facility utilizes Term SOFR plus an applicable margin (1.50% to 2.50%) or Alternative Base Rate plus a margin (0.50% to 1.50%), replacing the previous interest structure.
- Prepayment Terms: The new facility allows voluntary prepayment without premium or penalty, whereas the old facility terms are no longer applicable.
Guidance, Outlook, and Covenants
- Financial Covenants: The new agreement requires quarterly compliance with a Total Net Leverage Ratio of 4.00 to 1.00 through the quarter ending December 31, 2023, and 3.50 to 1.00 thereafter. An Interest Coverage Ratio of not less than 3.00:1.00 is also required.
- Contingent Financing: The $100.0 million delayed draw term loan is contingent on the failure of the proposed $500.0 million convertible notes offering. If the notes are issued, the commitment for the delayed draw term loan will terminate.
- Incremental Capacity: LMI has the right to request incremental term loans or increases to the revolving commitment up to an "Incremental Cap" based on Consolidated EBITDA.
- Use of Proceeds: Proceeds from the new revolving facility and potential incremental loans are designated for working capital and general corporate purposes.
Investor Verification Checklist
- Verify the final terms and pricing of the proposed $500.0 million convertible senior notes offering.
- Confirm whether the $100.0 million delayed draw term loan facility is drawn or terminated based on the outcome of the notes offering.
- Monitor the company's Total Net Leverage Ratio and Interest Coverage Ratio to ensure compliance with the new 4.00:1.00 and 3.00:1.00 covenants.
- Track the execution of the authorized $150.0 million stock repurchase program and its funding source.
- Review the specific interest rate margins applicable to the new facility based on the company's current Total Net Leverage Ratio.